X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
LIMITx™ LTX-03, works by neutralizing stomach acid with buffering ingredients as increasing numbers of tablets are swallowed thereby reducing the stomach acid available to cause the release and systemic absorption of active from micro-particles contained in the LIMITx tablets.
Lead Product(s): Hydrocodone Bitartrate,Paracetamol
Therapeutic Area: Neurology Product Name: LTX-03
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Abuse Deterrent Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 01, 2022
Details:
In clinical study, formulations of LTX-03 demonstrated, under fasted conditions, analgesic levels of hydrocodone in the blood when taken at a recommended one or two tablet dose but reduced the maximum blood level up to 34% when exposed to higher buffer ingredient levels.
Lead Product(s): Hydrocodone Bitartrate,Paracetamol
Therapeutic Area: Neurology Product Name: LTX-03
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2022
Details:
LTX-03 is an immediate-release hydrocodone bitartrate with acetaminophen tablet. The agreement aims at extending the FDA Acceptance Date for LTX-03 to February 28, 2022.
Lead Product(s): Hydrocodone Bitartrate,Paracetamol
Therapeutic Area: Neurology Product Name: LTX-03
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Abuse Deterrent Pharma, LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 26, 2021
Details:
LTX-03 (hydrocodone with acetaminophen) demonstrated, under fasted conditions, analgesic levels of hydrocodone in the blood when taken at a recommended one or two tablet dose.
Lead Product(s): Hydrocodone Bitartrate,Paracetamol
Therapeutic Area: Neurology Product Name: LTX-03
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2021
Details:
In conjunction with a third party formulation developer, the formulation and manufacturing process for LTX-03 has been optimized for commercial scale.
Lead Product(s): Hydrocodone Bitartrate,Paracetamol
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
